For more information, please visit www.accessvascularinc.com.
Access Vascular, Inc.
HydroMID features a novel biomaterial designed to reduce complications such as catheter occlusion & thrombosis events.
Founded 2015
Billerica, United States
65 employees
Series C
Total: $57.10M
Health Care, Manufacturing +1
Billerica, United States
65 employees
Series C
Total: $57.10M
Health Care, Manufacturing +1
General Information
Company Name
Access Vascular, Inc.
Founded Year
2015
Location
Billerica, United States
Billerica, United States
Employees
65
Industries
Health Care, Manufacturing, Medical Devices
Funding Stage
Series C
Social
BounceWatch is an independent company data service, not affiliated with Access Vascular, Inc.. To contact Access Vascular, Inc., visit accessvascularinc.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Access Vascular, Inc. compare?
A PDF of Access Vascular, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Access Vascular, Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Access Vascular, Inc. on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Health Care
About Access Vascular, Inc.
Business keywords: biomaterial, catheter occlusion, thrombosis, intravenous therapy, infection prevention, phlebitis, hydrophilic material, thrombus reduction, intravenous catheters, foreign body response, bioengineering, medical innovation
Funding Rounds & Investors (7)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | $22.00M | - |
|
31 Oct 2023 |
| Series B | $20.00M | 1 |
|
03 Mar 2021 |
| Venture Round | $6.00M | - |
|
26 Sep 2019 |
| Venture Round | $3.40M | 1 |
|
23 Aug 2018 |
| Venture Round | $1.92M | - |
|
18 May 2018 |
| Venture Round | $3.77M | 1 |
|
28 Aug 2017 |
| Grant | Undisclosed | 1 |
|
01 May 2017 |
Access Vascular, Inc. Alternatives & Competitors
Access Vascular, Inc. vs
Light Line Medical, Inc.
United States
Light Line has developed a proprietary method of delivering light to prevent and treat catheter asso...
Seed
20 employees
Health Care, Medical Devices
Access Vascular, Inc. vs
Nexus Medical
United States
U.S. Manufacturer of IV Therapy Solutions and Inventor of TKO Anti-Reflux Needleless Connectors for...
56 employees
Health Care, Manufacturing
FAQ About Access Vascular, Inc.
HydroMID features a novel biomaterial designed to reduce complications such as catheter occlusion & thrombosis events.
Access Vascular, Inc. was founded in 2015.
Access Vascular, Inc. is headquartered in Billerica, United States.
Access Vascular, Inc. operates in Health Care, Manufacturing and Medical Devices. Its work centres on biomaterial, catheter occlusion, thrombosis and intravenous therapy.
Access Vascular, Inc. has approximately 65 employees.
Access Vascular, Inc. has completed 7 funding rounds, raising a total of $57.10M. The latest funding stage is Series C.
Top alternatives and competitors to Access Vascular, Inc. include Light Line Medical, Inc., Nexus Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Access Vascular, Inc. and Light Line Medical, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Access Vascular, Inc., https://bouncewatch.com/company/access-vascular-inc, updated 28 November 2024. When citing, please name BounceWatch and link this page.
